Serum-Based Oxylipins Are Associated with Outcomes in Primary Prevention Implantable Cardioverter Defibrillator Patients

• Yiyi Zhang,

  Affiliation Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States of America

  ⨯
• Eliseo Guallar,

  Affiliation Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States of America

  ⨯
• Elena Blasco-Colmenares,

  Affiliation Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

  ⨯
• Amy C. Harms,

  Affiliation Netherlands Metabolomics Centre, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands

  ⨯
• Rob J. Vreeken,

  Affiliations Netherlands Metabolomics Centre, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands, Analytical Biosciences, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands, Discovery Sciences, Janssen R&D, Beerse, Belgium

  ⨯
• Thomas Hankemeier,

  Affiliations Netherlands Metabolomics Centre, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands, Analytical Biosciences, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands

  ⨯
• Gordon F. Tomaselli,

  Affiliation Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

  ⨯
• Alan Cheng

  * E-mail: alcheng@jhmi.edu

  Affiliation Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

  ⨯